Monomeric ENAMPT in the Development of Experimental Diabetes in Mice: a Potential Target for Type 2 Diabetes Treatment

Overview

Journal Diabetologia

Specialty Endocrinology

Date 2016 Aug 20

PMID 27541013

Citations 19

Authors

Julius Kieswich

Sophie R Sayers

Marta F Silvestre

Steven M Harwood

Muhammad M Yaqoob

Paul W Caton

Affiliations

Soon will be listed here.

Abstract

Aims/hypothesis: Serum extracellular nicotinamide phosphoribosyltransferase (eNAMPT) concentrations are elevated in type 2 diabetes. However, the relationship between abnormally elevated serum eNAMPT and type 2 diabetes pathophysiology is unclear. eNAMPT circulates in functionally and structurally distinct monomeric and dimeric forms. Dimeric eNAMPT promotes NAD biosynthesis. The role of eNAMPT-monomer is unclear but it may have NAD-independent proinflammatory effects. However, studies of eNAMPT in type 2 diabetes have not distinguished between monomeric and dimeric forms. Since type 2 diabetes is characterised by chronic inflammation, we hypothesised a selective NAD-independent role for eNAMPT-monomer in type 2 diabetes.

Methods: Two mouse models were used to examine the role of eNAMPT-monomer in type 2 diabetes; (1) a mouse model of diabetes fed a high-fat diet (HFD) for 10 weeks received i.p. injections with an anti-monomeric-eNAMPT antibody; and (2) lean non-diabetic mice received i.p. injections with recombinant monomeric eNAMPT daily for 14 days.

Results: Serum monomeric eNAMPT levels were elevated in HFD-fed mouse models of diabetes, whilst eNAMPT-dimer levels were unchanged. eNAMPT-monomer neutralisation in HFD-fed mice resulted in lower blood glucose levels, amelioration of impaired glucose tolerance (IGT) and whole-body insulin resistance, improved pancreatic islet function, and reduced inflammation. These effects were maintained for at least 3 weeks post-treatment. eNAMPT-monomer administration induced a diabetic phenotype in mice, characterised by elevated blood glucose, IGT, impaired pancreatic insulin secretion and the presence of systemic and tissue inflammation, without changes in NAD levels.

Conclusions/interpretation: We demonstrate that elevation of monomeric-eNAMPT plays an important role in the pathogenesis of diet-induced diabetes via proinflammatory mechanisms. These data provide proof-of-concept evidence that the eNAMPT-monomer represents a potential therapeutic target for type 2 diabetes.

Citing Articles

NAD World 3.0: the importance of the NMN transporter and eNAMPT in mammalian aging and longevity control.

Imai S NPJ Aging. 2025; 11(1):4.

PMID: 39870672 PMC: 11772665. DOI: 10.1038/s41514-025-00192-6.

Pathobiochemistry of Aging and Neurodegeneration: Deregulation of NAD+ Metabolism in Brain Cells.

Kolotyeva N, Groshkov A, Rozanova N, Berdnikov A, Novikova S, Komleva Y Biomolecules. 2025; 14(12.

PMID: 39766263 PMC: 11673498. DOI: 10.3390/biom14121556.

Adipokines and their potential impacts on susceptibility to myocardial ischemia/reperfusion injury in diabetes.

Han R, Huang H, Zhu J, Jin X, Wang Y, Xu Y Lipids Health Dis. 2024; 23(1):372.

PMID: 39538244 PMC: 11558907. DOI: 10.1186/s12944-024-02357-w.

Impact of Lipids on Insulin Resistance: Insights from Human and Animal Studies.

Elkanawati R, Sumiwi S, Levita J Drug Des Devel Ther. 2024; 18:3337-3360.

PMID: 39100221 PMC: 11298177. DOI: 10.2147/DDDT.S468147.

NAMPT, IL-6, and vaspin gene expressions and serum protein levels in type 2 diabetes mellitus and related complication.

Celik S, Parilti D, Acik L, Yalcin M, Yetkin I, Yunusov E Turk J Biol. 2024; 48(2):133-141.

PMID: 39051061 PMC: 11265895. DOI: 10.55730/1300-0152.2688.

References

Wang T, Zhang X, Bheda P, Revollo J, Imai S, Wolberger C . Structure of Nampt/PBEF/visfatin, a mammalian NAD+ biosynthetic enzyme. Nat Struct Mol Biol. 2006; 13(7):661-2. DOI: 10.1038/nsmb1114. View

Chen M, Chung F, Chang D, Tsai J, Huang H, Shin S . Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2005; 91(1):295-9. DOI: 10.1210/jc.2005-1475. View

Caton P, Nayuni N, Kieswich J, Khan N, Yaqoob M, Corder R . Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5. J Endocrinol. 2010; 205(1):97-106. DOI: 10.1677/JOE-09-0345. View

Birkenfeld A, Shulman G . Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology. 2013; 59(2):713-23. PMC: 3946772. DOI: 10.1002/hep.26672. View

Sun K, Kusminski C, Scherer P . Adipose tissue remodeling and obesity. J Clin Invest. 2011; 121(6):2094-101. PMC: 3104761. DOI: 10.1172/JCI45887. View

Yoshino J, Mills K, Yoon M, Imai S . Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 2011; 14(4):528-36. PMC: 3204926. DOI: 10.1016/j.cmet.2011.08.014. View

DeFronzo R, Abdul-Ghani M . Preservation of β-cell function: the key to diabetes prevention. J Clin Endocrinol Metab. 2011; 96(8):2354-66. DOI: 10.1210/jc.2011-0246. View

Boni-Schnetzler M, Donath M . How biologics targeting the IL-1 system are being considered for the treatment of type 2 diabetes. Br J Clin Pharmacol. 2012; 76(2):263-8. PMC: 3731600. DOI: 10.1111/j.1365-2125.2012.04297.x. View

Revollo J, Korner A, Mills K, Satoh A, Wang T, Garten A . Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab. 2007; 6(5):363-75. PMC: 2098698. DOI: 10.1016/j.cmet.2007.09.003. View

10.

Hara N, Yamada K, Shibata T, Osago H, Tsuchiya M . Nicotinamide phosphoribosyltransferase/visfatin does not catalyze nicotinamide mononucleotide formation in blood plasma. PLoS One. 2011; 6(8):e22781. PMC: 3149623. DOI: 10.1371/journal.pone.0022781. View

11.

Krzyzanowska K, Krugluger W, Mittermayer F, Rahman R, Haider D, Shnawa N . Increased visfatin concentrations in women with gestational diabetes mellitus. Clin Sci (Lond). 2006; 110(5):605-9. DOI: 10.1042/CS20050363. View

12.

Spinnler R, Gorski T, Stolz K, Schuster S, Garten A, Beck-Sickinger A . The adipocytokine Nampt and its product NMN have no effect on beta-cell survival but potentiate glucose stimulated insulin secretion. PLoS One. 2013; 8(1):e54106. PMC: 3546920. DOI: 10.1371/journal.pone.0054106. View

13.

Donath M, Shoelson S . Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011; 11(2):98-107. DOI: 10.1038/nri2925. View

14.

Imai S . Nicotinamide phosphoribosyltransferase (Nampt): a link between NAD biology, metabolism, and diseases. Curr Pharm Des. 2009; 15(1):20-8. PMC: 2734389. DOI: 10.2174/138161209787185814. View

15.

Moschen A, Gerner R, Tilg H . Pre-B cell colony enhancing factor/NAMPT/visfatin in inflammation and obesity-related disorders. Curr Pharm Des. 2010; 16(17):1913-20. DOI: 10.2174/138161210791208947. View

16.

Caton P, Richardson S, Kieswich J, Bugliani M, Holland M, Marchetti P . Sirtuin 3 regulates mouse pancreatic beta cell function and is suppressed in pancreatic islets isolated from human type 2 diabetic patients. Diabetologia. 2013; 56(5):1068-77. DOI: 10.1007/s00125-013-2851-y. View

17.

Yoon M, Yoshida M, Johnson S, Takikawa A, Usui I, Tobe K . SIRT1-Mediated eNAMPT Secretion from Adipose Tissue Regulates Hypothalamic NAD+ and Function in Mice. Cell Metab. 2015; 21(5):706-17. PMC: 4426056. DOI: 10.1016/j.cmet.2015.04.002. View

18.

Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon M . Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes. 2005; 54(10):2911-6. DOI: 10.2337/diabetes.54.10.2911. View

19.

Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R . Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab. 2006; 91(8):3165-70. DOI: 10.1210/jc.2006-0361. View

20.

Haider D, Holzer G, Schaller G, Weghuber D, Widhalm K, Wagner O . The adipokine visfatin is markedly elevated in obese children. J Pediatr Gastroenterol Nutr. 2006; 43(4):548-9. DOI: 10.1097/01.mpg.0000235749.50820.b3. View